OBIANUJU OKPALA: Open Payments
NPI 1093335853 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,583 in 75 payments from 10 companies in 2025. Trend: 2023 $1,292 · 2024 $1,362 · 2025 $1,583
Food & beverage: $1,579Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $401 |
| Janssen Pharmaceuticals, Inc | 6 | $255 |
| Teva Pharmaceuticals USA, Inc. | 17 | $230 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $167 |
| Alkermes, Inc. | 7 | $146 |
| Lundbeck LLC | 4 | $96 |
| E.R. Squibb & Sons, L.L.C. | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| ABBVIE INC. | 4 | $70 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
Products named: INGREZZA, INVEGA SUSTENNA, CAPLYTA, UZEDY, ARISTADA, ABILIFY ASIMTUFII, COBENFY, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
